XML 27 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaborative Arrangements (Details) (USD $)
 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 28 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Dec. 31, 2012
Sep. 30, 2013
Janssen Pharmaceutica, N.V.
Jun. 30, 2012
Janssen Pharmaceutica, N.V.
Sep. 30, 2013
Janssen Pharmaceutica, N.V.
Sep. 30, 2012
Janssen Pharmaceutica, N.V.
Dec. 31, 2006
Janssen Pharmaceutica, N.V.
Sep. 30, 2013
Mitsubishi Tanabe Pharma Corporation
Sep. 30, 2012
Mitsubishi Tanabe Pharma Corporation
Dec. 31, 2011
Mitsubishi Tanabe Pharma Corporation
Dec. 31, 2009
Mitsubishi Tanabe Pharma Corporation
Apr. 30, 2011
Cystic Fibrosis Foundation Therapeutics Incorporated
Sep. 30, 2013
Cystic Fibrosis Foundation Therapeutics Incorporated
payment
Sep. 30, 2012
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2012
Cystic Fibrosis Foundation Therapeutics Incorporated
Sep. 30, 2013
Cystic Fibrosis Foundation Therapeutics Incorporated
Sep. 30, 2012
Cystic Fibrosis Foundation Therapeutics Incorporated
Dec. 31, 2006
Cystic Fibrosis Foundation Therapeutics Incorporated
Jun. 30, 2013
Alios Bio Pharma Inc
Sep. 30, 2013
Alios Bio Pharma Inc
lines
Jun. 30, 2012
Alios Bio Pharma Inc
Sep. 30, 2013
Alios Bio Pharma Inc
lines
Sep. 30, 2012
Alios Bio Pharma Inc
Sep. 30, 2013
Alios Bio Pharma Inc
lines
Dec. 31, 2012
Alios Bio Pharma Inc
Schedule of Collaborative Arrangements                                                        
Drug development costs to be paid by collaborator (as a percent)           50.00%       50.00%                                    
Up-front license payment                   $ 165,000,000                                    
Deferred revenue related to up-front license payment           34,200,000   34,200,000                                        
Total contingent milestone payments earned           350,000,000                                            
Notice period required to terminate without cause (in years)           1 year                                            
Notice period required for termination after first commercial sale ( in years)           10 years                                            
Collaborative revenues recognized                                                        
Royalty revenues 27,012,000 25,586,000 119,705,000 98,047,000   20,994,000 19,957,000 104,108,000 80,811,000                                      
Amortized portion of up-front payment           3,107,000 3,107,000 9,321,000 9,321,000                                      
Net reimbursement (payment) for telaprevir development costs           1,413,000 (503,000) 1,422,000 (2,569,000)                                      
Reimbursement for manufacturing services           0 0 10,299,000 4,449,000                                      
Collaborative revenues 8,035,000 6,919,000 32,290,000 42,852,000   4,520,000 2,604,000 21,042,000 11,201,000   0 18,900,000       3,515,000   4,315,000 11,318,000 12,772,000                
Total revenues 221,700,000 336,006,000 860,818,000 1,193,048,000   25,514,000 22,561,000 125,150,000 92,012,000                                      
License fee paid upon amendment of agreement                           105,000,000                            
Milestone payment received                         65,000,000     9,300,000 9,300,000       1,500,000              
Notice period required to terminate without cause (in days)                     60 days                                  
Collaborative funding                             75,000,000                          
Number of years over which funding will be made (in years)                             5 years                          
Number of commercial milestone payments for achievement of certain sales levels for corrector compound such as VX-809 or VX-661 (in payments)                               2                        
Up-front payment                                           60,000,000            
Milestone payments                                                     60,000,000  
Development milestone payments, maximum                                                     312,500,000  
Commercial milestone payments, maximum                                             750,000,000          
Notice period for termination of contract due to technical failure (in days)                                             30 days          
Notice period for termination of contract after completion of clinical trials (in days)                                             60 days          
Latest expiration period for royalty obligation after first commercial sale in country unless contract is terminated earlier (in years)                                             10 years          
Noncontrolling Interest (Alios)                                                        
Number of lines on balance sheet where noncontrolling interest is reported                                             2   2   2  
Loss (income) before provision for (benefit from) income taxes                                             9,056,000 5,090,000 21,177,000 14,581,000    
Decrease (increase) in fair value of contingent milestone and royalty payments                                             (1,220,000) (57,560,000) 1,600,000 (112,760,000)    
Provision for (benefit from) income taxes (751,000) 21,355,000 (132,863,000) 41,450,000                                     (3,306,000) 21,394,000 (9,089,000) 40,354,000    
Net loss (income) attributable to noncontrolling interest (Alios) (4,530,000) 31,076,000 (13,688,000) 57,825,000                                     4,530,000 (31,076,000) 13,688,000 (57,825,000)    
Restricted cash and cash equivalents (Alios) 51,059,000 [1]   51,059,000 [1]   69,983,000 [1]                                   51,059,000   51,059,000   51,059,000 69,983,000
Prepaid expenses and other current assets 41,104,000 [1]   41,104,000 [1]   24,673,000 [1]                                   8,821,000   8,821,000   8,821,000 672,000
Property and equipment, net 648,924,000 [1]   648,924,000 [1]   433,609,000 [1]                                   1,374,000   1,374,000   1,374,000 1,728,000
Intangible assets                                             250,600,000   250,600,000   250,600,000 250,600,000
Goodwill 30,992,000 [1]   30,992,000 [1]   30,992,000 [1]                                   4,890,000   4,890,000   4,890,000 4,890,000
Other assets 3,474,000 [1]   3,474,000 [1]   9,668,000 [1]                                   153,000   153,000   153,000 861,000
Accounts payable 51,533,000 [1]   51,533,000 [1]   101,292,000 [1]                                   1,251,000   1,251,000   1,251,000 1,054,000
Accrued expenses 280,848,000 [1]   280,848,000 [1]   264,884,000 [1]                                   6,689,000   6,689,000   6,689,000 6,099,000
Deferred tax liability 150,203,000 [1]   150,203,000 [1]   280,367,000 [1]                                   150,203,000   150,203,000   150,203,000 152,781,000
Other liabilities, excluding current portion 10,782,000 [1]   10,782,000 [1]   13,902,000 [1]                                   873,000   873,000   873,000 1,625,000
Redeemable noncontrolling interest (Alios) 39,624,000 [1]   39,624,000 [1]   38,530,000 [1]                                   39,624,000   39,624,000   39,624,000 38,530,000
Noncontrolling interest (Alios) $ 182,168,000 [1]   $ 182,168,000 [1]   $ 196,672,000 [1]                                   $ 182,168,000   $ 182,168,000   $ 182,168,000 $ 196,672,000
[1] Amounts include the assets and liabilities of Vertex’s variable interest entity (“VIE”), Alios BioPharma, Inc. (“Alios”). Vertex’s interests and obligations with respect to the VIE’s assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note C, "Collaborative Arrangements," to these condensed consolidated financial statements for amounts.